

Sheet 1 of 2

Form TO-1449

**U.S. Department of Commerce
Patent and Trademark Office**

 Atty. Docket No.
50634-BA Serial No.
10/646,493

**INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**
Applicants
Eric Rose et al.

Filing Date
August 21, 2003

Group
U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JKR	US 5,839,443	Nov. 24, 1998	Eric Rose, et al.	128	898	
JKR	US 09/053,872		Eric Rose, et al.	—	—	April 1, 1998

FOREIGN PATENT DOCUMENTS


	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JKR	Bazan, J.F., "Big rigs in blood coagulation," <u>Nature</u> 380: 21-23, 03/1996
JKR	Benedict, C.R. et al., "Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model," <u>J. Clin. Invest.</u> , 88: 1760-1765, 1991.
JKR	Benedict, C.R. et al., "Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms," <u>Texas Heart Institute Journal</u> , 21: 86-90, 1994
JKR	Berntorp, E., "Biochemical and in vivo properties of high purity factor IX concentrates," <u>Thrombosis and Haemostasis</u> 70(5): 768-773, 11/1993
JKR	Freedman, S.J. et al., "Structure of the metal-free γ-carboxyglutamate acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy," <u>J. Biol. Chem.</u> , 270(14): 7980-7987, 04/1995
JKR	Furie, B.C. and Furie, B., "Biosynthesis of factor IX: implications for gene therapy," <u>Thrombosis and Haemostasis</u> , 74(1): 274-277 (1995)
JKR	Iberti, T.J. et al., "Abnormal coagulation profile in brain tumor patients during surgery," <u>Neurosurgery</u> , 34(3): 389-395, 03/1994
JKR	Kirchhofer, et al., "Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model," <u>Arterioscler. Thromb. Vasc. Biol.</u> , 15: 1098-1106 (1995)

EXAMINER	Jeffrey E. Russell	DATE CONSIDERED	December 16, 2004
----------	--------------------	-----------------	-------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

Form STO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 50634-BA		Serial No. 10/646,493	
					Applicants Eric Rose et al.			
					Filing Date August 21, 2003		Group	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>JR</i>	Kuwabara, K. et al., "Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries," <u>J. Biol. Chem.</u> , 270(14): 8179-8187, 04/1995							
<i>JR</i>	Miyata, T. et al., "Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling," <u>Brit. J. Of Haematol.</u> , 88(1): 156-165, 09/1994							
<i>JR</i>	Santagostino, E. et al., "Markers of hyper coagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery," <u>Thrombosis and Haemostasis</u> , 71(6): 737-40, 06/1994							
<i>JR</i>	Wacey, A.I. et al., "Determinants of the factor IX mutational spectrum in hemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein," <u>Hum. Genet.</u> , 94(6): 594-609, 12/1994							
<i>JR</i>	Warrier, I. et al., "Safety of high doses of a monoclonal antibody-purified factor IX concentrate, <u>Am. J. Of Hematol.</u> , 49(1): 92-94, 05/1995							
<i>JR</i>	Wong, A.G. et al., "Relative efficacy of active site-blocked factors IXa Xa in a model of venous thrombosis," <u>Supplement I Circulation</u> , Abstract # 3293 p. I-686, Vol. 92, No. 8. 10/1995							
EXAMINER	<i>Jeffrey E. Russell</i>	DATE CONSIDERED	December 16, 2004					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								